Immune-related adverse events in small-cell lung cancer patients treated with immune checkpoint inhibitors: a comprehensive analysis from the FDA adverse event reporting system

Immune-related adverse events in small-cell lung cancer patients treated with immune checkpoint inhibitors: a comprehensive analysis from the FDA adverse event reporting system

BackgroundThe discovery and development of immune checkpoint inhibitors (ICIs) have resulted in their application as a novel therapeutic strategy for patients with small-cell lung cancer (SCLC). However, a comprehensive analysis of the potential adverse effects of ICIs in patients with SCLC remains...

Full description

Bibliographic Details
Main Authors: Yifeng Bai, Xiaomei Wang, Xiaoqin Dai, Qinghua Ma, Honglin Hu
Format: Article
Language:English
Published: Frontiers Media S.A. 2024-10-01
Series:Frontiers in Pharmacology
Subjects:
SCLC
FDA adverse event reporting system (FAERS)
ICIs
immune check point inhibitors
irAEs (immune-related adverse events)
adverse (side) effects
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2024.1398667/full

Internet

https://www.frontiersin.org/articles/10.3389/fphar.2024.1398667/full

Similar Items